Report from Gambro's Annual General Meeting, March 21, 2001

Report from Gambro's Annual General Meeting, March 21, 2001 Stockholm, Sweden, March 21, 2001 - Gambro AB (OM Stockholm Exchange: GAMBaST, GAMBbST), a leading international medical technology and healthcare company, today reported the following decisions taken at the Annual General Meeting. Board of Directors Claes Dahlbäck, Gösta Gahrton, Peter H. Grassmann, Juha P. Kokko, Håkan Mogren, Sven Nyman and Björn Svedberg were reelected members of the Board. Mikael Lilius had declined reelection. Sandra Austin Crayton, Bill Gantz and Sören Mellstig were elected new members of the Board. At the statutory Board meeting following the Annual General Meeting, Claes Dahlbäck was elected Chairman and Håkan Mogren was elected Vice Chairman. Dividend The Meeting approved a dividend for 2000 of SEK 1.10 per share, with a record date of March 26, 2001. With this record date, dividends are expected to be paid from VPC (The Swedish Central Securities Depository and Clearing Organisation) on March 29, 2001. Purchase and sale of the Company's own shares The proposed authority for the Board to decide on the purchase and sale of the Company's own shares was approved. In short this includes authority for the Board to decide on the acquisition of own shares subject to certain conditions as well as authority to dispose of own shares subject to certain conditions. For further information please contact: Bengt Modéer, Investor Relations, tel. +46-8-613 65 00, +46-70-513 65 33 Karin Avasalu, Corporate Communications, tel. +46-8-613 65 00, +46-70- 513 65 99 Gambro is a global medical technology and healthcare company with leading positions in renal care - services and products - and blood component technology. Gambro Healthcare is one of the leading providers of kidney dialysis services in the world with about 47,000 patients in 600 clinics worldwide. Gambro Renal Products comprises dialyzers, dialysis machines, blood lines and dialysis concentrates. Gambro BCT includes products for the separation and handling of blood components. The group, with revenue of approximately SEK 22 billion (USD 2.4 billion), has approximately 18,000 employees in some 40 countries. ------------------------------------------------------------ This information was brought to you by BIT http://www.bit.se The following files are available for download: http://www.bit.se/bitonline/2001/03/21/20010321BIT00600/bit0002.doc http://www.bit.se/bitonline/2001/03/21/20010321BIT00600/bit0002.pdf